Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Surgical Endoscopy
|
December 6, 2006
BMI affects presenting symptoms of achalasia and outcome after Heller myotomy
S S Rakita, D Villadolid, C Kalipersad, et al.
American Journal of Clinical Oncology
|
June 11, 1999
Marimastat in patients with advanced pancreatic cancer: a dose-finding study
A Rosemurgy, J Harris, A Langleben, et al.
Current Surgery
|
January 1, 1983
Design and anatomic location of the ileal reservoir determine functional results after ileoanal anastomosis
A A Rosemurgy, W H Schraut, C H Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2001
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial
S R Bramhall, A Rosemurgy, P D Brown, et al.
The American Surgeon
|
June 21, 2001
Delay in treatment of biliary disease during pregnancy increases morbidity and can be avoided with safe laparoscopic cholecystectomy
J Muench, M Albrink, F Serafini, et al.
The Journal of Surgical Research
|
July 18, 2000
Videoscopic Heller myotomy for achalasia--results beyond short-term follow-up
M Bloomston, W Boyce, J Mamel, et al.
The Journal of Emergency Medicine
|
March 1, 1993
System care improves trauma outcome: patient care errors dominate reduced preventable death rate
E Thoburn, P Norris, R Flores, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 1998
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies
J Nemunaitis, C Poole, J Primrose, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2006
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
D A Richards, K A Boehm, D M Waterhouse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
T R J Evans, E Van Cutsem, M J Moore, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Surgical Endoscopy
|
December 6, 2006
BMI affects presenting symptoms of achalasia and outcome after Heller myotomy
S S Rakita, D Villadolid, C Kalipersad, et al.
American Journal of Clinical Oncology
|
June 11, 1999
Marimastat in patients with advanced pancreatic cancer: a dose-finding study
A Rosemurgy, J Harris, A Langleben, et al.
Current Surgery
|
January 1, 1983
Design and anatomic location of the ileal reservoir determine functional results after ileoanal anastomosis
A A Rosemurgy, W H Schraut, C H Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2001
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial
S R Bramhall, A Rosemurgy, P D Brown, et al.
The American Surgeon
|
June 21, 2001
Delay in treatment of biliary disease during pregnancy increases morbidity and can be avoided with safe laparoscopic cholecystectomy
J Muench, M Albrink, F Serafini, et al.
The Journal of Surgical Research
|
July 18, 2000
Videoscopic Heller myotomy for achalasia--results beyond short-term follow-up
M Bloomston, W Boyce, J Mamel, et al.
The Journal of Emergency Medicine
|
March 1, 1993
System care improves trauma outcome: patient care errors dominate reduced preventable death rate
E Thoburn, P Norris, R Flores, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 1998
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies
J Nemunaitis, C Poole, J Primrose, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2006
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
D A Richards, K A Boehm, D M Waterhouse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
T R J Evans, E Van Cutsem, M J Moore, et al.
Page
of 2